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Background: Hypoxic tumours exhibit increased resistance to radiation, chemical, and immune therapies.
18F-fluoromisonidazole (FMISO) positron emission tomography (PET) is a non-invasive, quantitative imaging
technique used to evaluate the presence and spatial distribution of tumour hypoxia. To facilitate the use of
FMISO PET for identification of individuals likely to benefit from hypoxia-targeted treatments, we investigated
the reproducibility of FMISO PET spatiotemporal intratumour distribution in patients with non-small cell lung
cancer (NSCLC).
Methods: Ten patients underwent 18F-fluorodeoxyglucose (FDG) PET/CT scans, followed by two FMISO PET/CT
scans 1–2 days apart. Nineteen lesions in total were segmented from co-registered FDG PET image sets. Volumes of
interest were also defined on normal contralateral lung and subscapularis muscle. The Pearson correlation coefficient r
was calculated for mean standardized uptake values (SUV) within investigated volumes of interest and for voxels within
tumour volumes (rTV). The reproducibility of FMISO voxelwise distribution, SUV- and tumour-to-blood ratio (TBR)-derived
indices was assessed using correlation and Bland-Altman analyses.
Results: The SUVmax, SUVmean, TBRmax, and TBRmean were highly correlated (r ≥ 0.87, p < 0.001) and were reproducible to
within 10–15 %. The mean rTV was 0.84 ± 0.10. 77 % of voxels identified as hypoxic on one FMISO scan were confirmed as
such on the other FMISO scan. Mean voxelwise differences between TBR values as calculated from pooled data including
all lesions were 0.9 ± 10.8 %.
Conclusions: High reproducibility of FMISO intratumour distribution in NSCLC patients was observed, facilitating its use in
determining the topology of the hypoxic tumour sub-volumes for dose escalation, in patient stratification strategies for
hypoxia-targeted therapies, and in monitoring response to therapeutic interventions.
Trial registration: Current Controlled Trials NCT02016872
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Non-small cell lung cancer (NSCLC) remains the leading
cause of cancer-related mortality worldwide [1]. Tumour-
cell hypoxia, a common feature of solid tumours, is a pivo-
tal determinant of the effectiveness of radiation, chemical,
and immune therapies and is associated with poor overall
survival [2, 3]. The hypoxic microenvironment can be* Correspondence: grkovskm@mkscc.org
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the Creative Commons license, and indicate ifassessed by a variety of approaches, e.g. by measurement of
partial pressure of oxygen with polarographic electrodes [4]
or by immunohistochemical detection of endogenous and
exogenous hypoxia markers [5]. However, such procedures
are invasive and potentially hazardous, restricted to ac-
cessible lesions, and limited by sampling errors.
18F-fluoromisonidazole (FMISO) positron emission tom-
ography (PET), a non-invasive imaging technique, presents
an attractive alternative [6–8]. FMISO is clinically the most
extensively investigated hypoxia PET tracer. Several studies
in lung cancer patients have suggested stratificationis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Table 1 Patient characteristics
Patient Age (years) Gender Stagea Histopathology
1 63 F IV Adenocarcinoma
2 75 F IIA Adenocarcinoma
3 72 F IB Squamous cell carcinoma
4 31 M IIIB Adenocarcinoma
5 63 M IIIB Adenocarcinoma
6 77 M IIIB Squamous cell carcinoma
7 70 M IIA Squamous cell carcinoma
8 56 F IIIB Adenocarcinoma
9 59 M IIIA Adenocarcinoma
10 73 M IIIA Adenocarcinoma
aAmerican Joint Committee on Cancer 7th Edition
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The hypothesis is that selective dose painting of putative
radioresistant hypoxic tumour sub-volumes, as defined by
FMISO PET, may improve locoregional control [13]. Nu-
merous efforts also continue to evaluate 18F-fluorodeoxy-
glucose (FDG) PET for target delineation in radiotherapy
[14, 15] and explore the utility of intensity-modulated
radiotherapy (IMRT) based on FDG voxel intensities
[16, 17]. However, despite a number of ongoing hypoxia-
imaging trials, quantitative assessment of intratumour
distribution of hypoxia-specific PET tracers has yet to
be widely implemented in the clinical decision-making
process.
In order to fully exploit the benefits of incorporating
tumour hypoxia information as obtained by FMISO PET
into patient management, whether as an IMRT target, in
patient stratification strategies for hypoxia-targeting regi-
mens, or for monitoring response to therapeutic interven-
tions, it is essential to examine the spatiotemporal
reproducibility of FMISO intratumour distribution. To our
knowledge, such studies have been performed only in head
and neck cancer (HNC) patients, with discordant results
[18, 19]. Due to the absence of similar studies in other
tumour entities, e.g. lung cancer, it remains unclear to what
extent the reproducibility of FMISO will be affected by the
lack of rigid immobilization and the presence of respiratory
motion. Therefore, the aim of this pilot study was to inves-
tigate the reproducibility of FMISO intratumoural distribu-




This study was approved by Memorial Sloan Kettering
Cancer Center’s Institutional Review Board (IRB 13-186;
registered under www.clinicaltrials.gov identifier number
NCT02016872), and all subjects signed a written in-
formed consent regarding the examination and use of
anonymized data for research and publication purposes.
The methods were carried out in accordance with the
approved guidelines.
Patient characteristics
The eligibility criteria were as follows: age > 18 years,
pathological confirmation of NSCLC, no prior treatment,
primary or nodal tumour measuring ≥2 cm on CT, and a
Karnofsky performance status of ≥70 %. Exclusion criteria
included pregnant or breast-feeding women and patients
with severe diabetes (fasting blood glucose >200 mg/dl).
Fifteen patients agreed to participate in the study. Patients
were scanned on a flat-top couch insert and immobilized
in an alpha cradle (Smithers Medical Products, Inc.). As
the second FMISO PET scan was not acquired for five
patients due to their inability to continue (n = 3) ortechnical reasons (n = 2), ten patients in total were in-
cluded in the reproducibility analysis (Table 1).
18F-fluorodeoxyglucose PET/CT protocol
Each patient underwent an FDG PET/CT study scan
for radiotherapy simulation purposes. Patients were
injected intravenously with 460 ± 17 MBq (range, 429–
477 MBq) of FDG, after a fasting period of ≥6 h. PET
scans were acquired for 3 min/bed position, at 100 ±
38 min (range, 60–171 min) post-injection (pi). All PET
data were acquired in 3D mode on a General Electric
Discovery ST PET/CT (GE Health Care Inc.). A CT ac-
quired in cine mode (140 kVp, 10 mA, 5.0-mm slice
thickness, 0.5-s tube rotation) was averaged (CTavg) and
used for attenuation correction of PET images. The
cine duration was set to match the patient breathing
period plus 1 s (~6 s on average). PET emission data
were corrected for attenuation, scatter, and random
events and reconstructed into 128 × 128 × 47 matrix
(voxel dimensions 5.47 × 5.47 × 3.27 mm). The recon-
struction was performed using the GE ordered subset
expectation maximization (OSEM) algorithm with stand-
ard clinical reconstruction parameters: 2 iterations, 16
subsets, and 6.0 mm full width at half maximum Gaussian
post-filter.
18F-fluoromisonidazole PET/CT protocol
Ten patients underwent two FMISO PET studies each
(i.e. FMISO1 and FMISO2). FMISO1 was performed
2.4 ± 1.4 days (range, 1–5 days) after the FDG PET/CT,
with FMISO2 being performed 1.7 ± 1.6 days (range, 1–
6 days) after FMISO1. Patients received an average FMISO
bolus injection of 388 ± 15 MBq (range, 356–407 MBq).
Data were acquired for 10 min over one field of view
(~15 cm; centred on the lesions) at 163 ± 13 min pi (range,
144–183 min). A low-dose cine CT scan (the same parame-
ters as for the FDG study) was performed and used for at-
tenuation correction and image co-registration. All FMISO
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Image analysis
The FDG and FMISO2 tumour volumes were co-registered
to those of FMISO1 by means of their corresponding CTavg
image sets, using the GE AW Workstation v4.6 General
Co-Registration tool (GE Health Care Inc.). Rigid trans-
formation was used, and the results were visually inspected
for potential mismatches. The transformation matrices
obtained were then applied to the corresponding PET
images. Tumour metabolic target volumes (TV) were delin-
eated on the FDG PET images with the adaptive threshold
algorithm in the GE AW Workstation PET VCAR™
(Volume Computer-Assisted Reading) semi-automated
software (FDA-approved), which is based on the com-
panion CT as a fiduciary marker and a count-based
edge recognition algorithm. The corresponding target
volumes were subsequently copied onto the two co-
registered FMISO image sets.
Tumour uptake in the target volumes on the two
FMISO scans was compared on a voxel-by-voxel basis in
PMOD v3.604 (PMOD Technologies GmbH). Activity
concentration data were converted into standardized
uptake values (SUV; normalized to lean body mass). The
blood SUV (SUVblood) was measured by (i) segmenting
the descending aorta on the CTavg, (ii) copying the
volume of interest (VOI) to the corresponding FMISO
PET, (iii) eroding the VOI by 1 voxel in 3D, and (iv)
measuring the average SUV within the eroded VOI.
Hypoxic sub-volume (HTV; in cm3) was defined as in-
cluding voxels within the TV having a tumour-to-blood
ratio (TBR) ≥ 1.2 on both FMISO scans [8]. For each
esion, maximum and mean values for voxels within the
TV were calculated in units of SUV (SUVmax, SUVmean)
and TBR (TBRmax, TBRmean). Reproducibility of FMISO
uptake was also assessed in the non-diseased normal
lung tissue (by evaluating the mean SUV within a 20-
mm-diameter spherical VOI that was placed in the
healthy contralateral lung; SUVlung) and in the non-
diseased muscle (by evaluating the mean SUV within a
manually drawn VOI on the subscapularis muscle on the
CTavg and subsequently copied to the corresponding
PET FMISO scan; SUVmuscle).
Statistical analysis
The Pearson correlation coefficient was calculated
between the FMISO1 and FMISO2 intratumour distribu-
tions (rTV) and between all SUV- and TBR-derived indi-
ces. The normality of the distribution of differences in
the investigated parameters between the two FMISO
studies was verified with a two-sample Kolmogorov-
Smirnov test. This was done to validate the applicability
of Bland-Altman analysis, which was subsequentlyperformed to calculate the mean differences between
voxelwise TBR values and 95 % limits of agreement (LoA)
[20]. The latter are defined as ±1.96 * SD of the mean dif-
ferences and represent the boundaries within which 95 %
of observations are expected to be observed. p < 0.05 was
assumed to represent statistical significance. To evaluate
the geographic stability of hypoxic sub-volumes, the per-
centage of intratumour voxels that were identified as hyp-
oxic in both FMISO studies was calculated, as based on
the TBR ≥ 1.2, ≥1.4, and ≥1.6 thresholds [6–9]. All statis-
tical analyses were carried out in MedCalc v15.6 (MedCalc
Software bvba).
Results
Nineteen FDG-avid lesions were included in the analysis.
None of the investigated lesions were located near the
edge of the PET field of view. The average lesion volume
was 28 cm3 (range, 4–111 cm3). No lesions were found
that would exhibit uptake on the FMISO scan while
being negative on the corresponding FDG scan. As mis-
matches between PET and CT scans were identified in
two patients (#4 and #9), the co-registrations were modi-
fied manually based on the PET images. All differences
between the FMISO1 and FMISO2 scans in the SUV-
and TBR-derived parameters, imaging time pi, and
injected dose were normally distributed, as assessed with
Kolmogorov-Smirnov test (p > 0.05). Tumour volume,
imaging time pi, SUVblood, SUVlung, SUVmax, SUVmean,
TBRmax, TBRmean, HTV, and rTV are summarized in
Table 2. Significantly high correlations were observed
between all SUV- and TBR-derived parameters from the
first and second FMISO scans (r ≥ 0.87, p < 0.001) and
HTV (r = 0.99, p < 0.001).
Scatter plots for the co-registered FMISO images display
intratumour voxels colour-coded according to their hyp-
oxia status as based on the TBR ≥ 1.2 threshold (Fig. 1).
The mean rTV was 0.84 ± 0.10 (range, 0.52–0.95), with all
lesions except for one having rTV > 0.70. The hypoxic sta-
tus (i.e. the presence of intratumour voxels with TBR
above the pre-defined threshold) remained unchanged in
nine out of ten patients between the two scans, regardless
of the implemented threshold. 77 %, 68 %, and 63 % of
voxels identified as hypoxic on one FMISO scan were con-
firmed as such on the other FMISO scan (based on TBR ≥
1.2, ≥1.4, and ≥1.6, respectively).
No significant correlation could be established between
SUVlung or SUVmuscle and SUVmax, SUVmean, TBRmax, or
TBRmean. The muscle-to-blood ratio, defined as SUVmuscle/
SUVblood, was 0.97 ± 0.11 across the patients, confirming
that FMISO uptake for non-diseased normoxic tissues ap-
proaches unity. Representative FMISO PET/CT images
from both scans are displayed for two patients (Fig. 2).
Bland-Altman analysis revealed that voxelwise SUV-
and TBR-derived indices were reproducible to within
Table 2 Summary of FMISO PET reproducibility analysis in patients with non-small cell lung cancer
Patient
(lesion)
TV (cm3) Scan time
pi (min)
SUVlung SUVmuscle SUVmax SUVmean TBRmax TBRmean HTV (cm
3) rTV
FMISO1 FMISO2 FMISO1 FMISO2 FMISO1 FMISO2 FMISO1 FMISO2 FMISO1 FMISO2 FMISO1 FMISO2 FMISO1 FMISO2 FMISO1 FMISO2
1 (1) 9.7 146 144 0.31 0.34 0.86 0.86 1.31 1.13 0.92 0.83 1.53 1.19 1.07 0.87 3.0 0.0 0.83
2 (2) 36.6 153 150 0.25 0.26 0.94 0.94 1.86 1.90 1.18 1.34 1.97 1.92 1.25 1.36 19.6 25.7 0.93
3 (3) 15.6 175 178 0.37 0.31 0.94 1.01 1.34 1.52 1.05 1.06 1.37 1.20 1.06 1.02 1.8 0.1 0.72
4 (4) 41.6 179 183 0.38 0.39 1.28 1.20 1.52 1.62 1.26 1.18 1.50 1.56 1.13 1.14 13.8 13.7 0.52
4 (5) 20.1 1.64 2.11 1.23 1.42 1.50 2.02 1.13 1.27 7.7 11.1 0.83
5 (6) 52.3 171 176 0.16 0.19 1.14 1.22 2.05 2.08 1.35 1.49 1.56 1.48 1.03 1.07 9.2 10.0 0.87
5 (7) 33.5 1.95 2.00 1.28 1.39 1.48 1.44 0.97 1.00 5.8 7.8 0.95
5 (8) 7.0 1.15 1.24 0.92 1.02 0.88 0.89 0.70 0.73 0.0 0.0 0.92
6 (9) 110.6 161 165 0.36 0.37 1.03 1.08 1.50 1.58 1.20 1.27 1.50 1.46 1.20 1.18 65.1 56.9 0.80
7 (10) 19.4 156 158 0.32 0.31 1.04 0.98 1.51 1.35 1.19 1.11 1.24 1.17 0.97 0.96 0.3 0.0 0.87
7 (11) 7.5 1.40 1.52 1.15 1.21 1.15 1.31 0.94 1.04 0.0 1.0 0.91
8 (12) 31.6 166 182 0.40 0.38 0.91 0.87 1.42 1.34 0.98 0.99 1.41 1.38 0.97 1.02 1.5 2.3 0.72
8 (13) 61.0 2.19 1.85 1.25 1.21 2.16 1.91 1.23 1.25 30.7 32.6 0.92
8 (14) 17.1 1.90 1.85 1.15 1.11 1.88 1.91 1.14 1.14 6.7 6.8 0.94
8 (15) 4.1 1.05 0.87 0.74 0.69 1.04 0.90 0.73 0.71 0.0 0.0 0.83
9 (16) 23.5 165 148 0.32 0.27 0.91 0.83 1.22 0.91 0.90 0.64 1.11 0.96 0.81 0.68 0.0 0.0 0.81
10 (17) 12.9 164 147 0.28 0.31 1.01 1.06 1.12 1.20 0.83 0.94 1.29 1.30 0.95 1.02 0.7 1.9 0.90
10 (18) 8.1 0.98 1.12 0.79 0.85 1.13 1.21 0.91 0.92 0.0 0.0 0.88
10 (19) 10.1 0.93 1.06 0.72 0.84 1.06 1.15 0.82 0.91 0.0 0.0 0.80
Maximum 110.6 179 183 0.40 0.38 11.28 1.22 2.19 2.09 1.35 1.49 2.16 2.02 1.25 1.36 65.1 56.9 0.95
Minimum 4.1 146 144 0.16 0.19 0.82 0.83 0.93 0.87 0.72 0.64 0.88 0.89 0.70 0.68 0.0 0.0 0.52














































Fig. 1 Reproducibility of FMISO intratumor distribution in patients with NSCLC. Voxelwise scatter plots of tumour-to-blood ratio in FMISO1 (x-axis) vs.
FMISO2 (y-axis) are presented for all 19 lesions. Black, blue, and red voxels represent normoxic, hypoxia-ambiguous, and hypoxic tumour sub-volumes,
respectively, as based on the TBR ≥ 1.2 threshold (dashed lines). Equality lines (dotted) and rTV are also displayed for all scatter plots. rTV values were
significant in all cases
Grkovski et al. EJNMMI Research  (2016) 6:79 Page 5 of 98–13 %, as calculated from 95 % confidence intervals of
the mean differences for each lesion (Table 3). Limits of
agreement were between 12 % (SUVmuscle) and 27 %
(SUVmax). Percentages are reported instead of absolute
values, to facilitate direct comparison of results across
different indices. Voxelwise Bland-Altman analysis
revealed an average relative difference of 0.9 ± 10.8 %
between FMISO1 and FMISO2, as calculated from
pooled data including all 19 lesions (n = 5320 voxels;
Table 4, Fig. 3). The associated limits of agreement
indicate that for 95 % of cases, the relative differences
will be within 22 %.
Discussion
It is important to determine the reproducibility of image-
based prognostic and predictive parameters, including
those deduced from nuclear medicine images, whichtypically exhibit greater statistical variation (i.e. noise) than
other modalities. This is especially true for hypoxia-
selective radiotracers such as FMISO in light of its gener-
ally low tumour uptakes and tumour-to-background ratios.
An evaluation of the reproducibility of FMISO PET in
NSCLC is a prerequisite if FMISO images are to be ration-
ally used in stratification of NSCLC patients for hypoxia-
targeting regimens, monitoring response to therapeutic
interventions, or to determine the topology of the hypoxic
tumour sub-volumes for dose escalation.
Our data showed strong correlations for both SUV-
and TBR-derived metrics between repeated FMISO
scans, corroborating results from FDG and 18F-flortani-
dazole (HX4) PET scans of NSCLC patients [21–23].
TBRmax and TBRmean were as reproducible as SUVmax
and SUVmean, despite the fact that the definition of a






Fig. 2 FMISO PET images of two patients with non-small cell lung cancer. From left to right: coronal, axial, and sagittal slices showing the first (upper row)
and second (lower row) FMISO PET scans of a patient #2 (lesion #2) and b patient #5 (lesion #7). PET images are windowed at 0–1.8 (a) and
0–1.4 (b) tumour-to-blood ratio, respectively
Grkovski et al. EJNMMI Research  (2016) 6:79 Page 6 of 9introduces additional source of variability. The classifica-
tion status (i.e. indicating either the presence or absence
of tumour hypoxia) as based on one FMISO scan
remained unchanged in the majority (9/10) of patients
when reassessment was performed using the other
FMISO scan. These results are encouraging in the
context of using FMISO PET in stratification of NSCLC
patients for hypoxia-targeted treatments. Changes in
FMISO uptake were reported to measure the early
response to chemoradiotherapy in NSCLC [10]; however,it remains unclear to what extent the spatiotemporal vari-
ability of FMISO PET affects the quality of monitoring
treatment response.
Data on the reproducibility of FMISO intratumour dis-
tributions from serial FMISO PET scans have been pre-
sented previously only for HNC patients, in two separate
studies by Nehmeh et al. [18] followed by Okamoto
et al. [19]. While Nehmeh et al. reported variability in
spatial uptake, speculating that the possible differences
were observed due to transient hypoxia, Okamoto et al.
(FMISO1 + FMISO2)/2


























95% Lower LoA: -22.1%
95% Upper LoA: 20.3%
Fig. 3 Bland-Altman analysis results for pooled data from all 19 lesions.
Relative differences in voxelwise TBR values are shown against the
average value combined from the two FMISO scans. Mean and both
upper and lower limits of agreement (LoA) are displayed as red and
blue lines, respectively
Table 3 Bland-Altman analysis results for all image-derived
features
KS test (p value) Mean ± SD (95 % CI) (%) LLA, ULA (%)
SUVblood 0.97 1 ± 8 (−5 to 7) −15, 17
SUVmax 0.96 −1 ± 13 (−6 to 7) −27, 25
SUVmean 0.96 1 ± 11 (−4 to 7) −21, 24
TBRmax 1.00 −2 ± 12 (−7 to 4) −25, 22
TBRmean 0.96 1 ± 9 (−3 to 5) −16, 18
SUVlung 0.96 0 ± 10 (−7 to 7) −19, 20
SUVmuscle 0.98 0 ± 6 (−4 to 4) −12, 12
KS Kolmogorov-Smirnov, CI confidence interval, LLA lower limit of agreement,
ULA upper limit of agreement
Grkovski et al. EJNMMI Research  (2016) 6:79 Page 7 of 9subsequently showed that FMISO intratumour distribu-
tions were highly reproducible. These contradictory
observations may be attributable to (i) imaging at differ-
ent times post-injection (162 ± 21 vs. 262 ± 21 min), (ii)
differences between scan times post-injection for the
two FMISO studies (13 ± 8 vs. 3 ± 3 %), (iii) different
acquisition times and modes (8 min in 2D mode vs. 10 min
in 3D), (iv) different PET/CT cameras (GE Discovery LS
with an axial field of view of 15.2 cm vs. newer generation
Siemens TruePoint Biograph with an axial field of view of
21.6 cm), and (v) different co-registration algorithms usedTable 4 Bland-Altman analysis results for differences between
voxelwise tumour-to-blood ratio values
Lesion # Mean ± SD (95 % CI) LLA, ULA
1 −0.21 ± 0.12 (−0.45 to 0.04) −0.45, 0.04
2 0.11 ± 0.10 (0.10 to 0.12) −0.09, 0.31
3 −0.04 ± 0.09 (−0.05 to −0.03) −0.21, 0.13
4 −0.01 ± 0.13 (−0.03 to 0.00) −0.26, 0.23
5 0.14 ± .19 (0.11 to 0.17) −0.23, 0.51
6 0.04 ± 0.09 (0.03 to 0.05) −0.13, 0.21
7 0.04 ± 0.07 (0.03 to 0.05) −0.11, 0.18
8 0.04 ± 0.04 (0.03 to 0.05) −0.04, 0.13
9 −0.03 ± 0.09 (−0.03 to −0.02) −0.20, 0.15
10 −0.01 ± 0.06 (−0.02 to −0.01) −0.12, 0.09
11 0.10 ± 0.05 (0.09 to 0.11) 0.00, 0.20
12 0.05 ± 0.09 (0.04 to 0.06) −0.13, 0.24
13 0.01 ± 0.11 (0.00 to 0.02) −0.20, 0.22
14 0.01 ± 0.10 (−0.01 to 0.02) −0.19, 0.20
15 0.09 ± .07 (0.07 to 0.11) −0.05, 0.22
16 −0.13 ± 0.07 (−0.14 to −0.12) −0.28, 0.01
17 0.07 ± 0.07 (0.06 to 0.08) −0.06, 0.20
18 0.01 ± 0.07 (0.00 to 0.02) −0.12, 0.14
19 0.08 ± 0.07 (0.07 to 0.10) −0.05, 0.22
Pooled data 0.01 ± 0.12 (0.01 to 0.02) −0.22, 0.24
CI confidence interval, LLA lower limit of agreement, ULA upper limit of agreementin the studies by Nehmeh et al. and Okamoto et al.,
respectively.
Okamoto and colleagues further speculated that an-
other potential reason for the discrepancy between the
two studies might have been imaging time post-injection
and considered imaging at 4+ h to be more suitable, due
to slow clearance of FMISO from the blood [19]. While
longer waiting periods should in principle increase the
contrast (and image noise), our results indicate that for
non-small lung cancer, similarly high reproducibility can
be obtained when imaging already at 2.5 h post-
injection. The mean rTV (0.84 ± 0.10) is comparable to
the results from Okamoto et al. (0.89 ± 0.09 [19]),
though not with those from Nehmeh et al. (0.60 ± 0.14
[18]). While in the current study patients were imaged
at 163 ± 13 min pi, there are several differences in the
methodology compared to that by Nehmeh and col-
leagues [18]: (i) variations in scan times were substan-
tially lower (5 ± 4 %), (ii) data were acquired in 3D mode
for 10 min, (iii) image acquisition was performed on a
more recent version of the GE PET/CT scanner, and (iv)
a different (FDA-approved) image co-registration soft-
ware was used compared to the previous study which
utilized in-house image co-registration software [18].
The quality of co-registrations may have additionally
affected the voxelwise correlation (for example, deliber-
ate misregistration by a single voxel in patient #3
resulted in a drop of rTV from 0.72 to 0.17).
More recently, reproducibility of hypoxia imaging
using HX4 PET has been investigated by Zegers and col-
leagues in a multicenter trial in both HNC and NSCLC
patients [23]. The authors concluded that HX4 PET
imaging is reproducible regarding the spatial uptake in
both HNC and NSCLC patients, reporting no major
Grkovski et al. EJNMMI Research  (2016) 6:79 Page 8 of 9differences in the results between the two cohorts [23].
The mean ΔSUV was 0.02 ± 0.07; high correlations were
reported between SUVmax and TBRmax as well as
between hypoxic sub-volumes [23]. Our results are also
in concordance with this study.
Scatter plots indicate systematic differences in voxelwise
uptake between the two FMISO scans, also observed in
earlier PET reproducibility studies [18, 19, 23]. Various
technical (e.g. incorrect synchronization of time between
injection and calibration), biologic (uptake period, pres-
ence of acute hypoxia, patient motion, breathing, and
comfort), and physical factors (VOI for the calculation of
SUVblood) might affect PET quantification [24]. However,
the mean difference in voxelwise TBR values from pooled
data was 0.9 ± 10.8 %, suggesting no systematic biases.
This observation is further supported by the absence of
significant correlation between SUV values in normal
tissues (contralateral lung and subscapularis muscle) and
in the tumour. Approximately 23 % of voxels identified as
hypoxic on one FMISO scan did not meet the hypoxia
criterion on the other FMISO scan (assuming the TBR >
1.2 threshold). In addition to the aforementioned factors,
this could be attributed to relatively low uptake of FMISO
that exacerbates the impact of statistical noise, potential
mismatch between the PET and the CT images (affecting
attenuation correction), CT-CT co-registration of the
FMISO1 to FMISO2 image sets, and/or the susceptibility
of the lesion to respiratory motion due to its location
within the lung. Resampling of FMISO2 resulted on aver-
age in <3 % absolute differences in uptake values. When
correlation analysis was repeated by co-registering
FMISO1 to FMISO2, the change in rTV was <1 % (data
not shown). The extent to which the changes in spatial
distribution of tumour hypoxia compromise the coverage
of hypoxic tumour sub-volumes achievable by IMRT
remains to be investigated.
A limitation of the current study is a small sample
size. Nevertheless, high reproducibility of FMISO spatio-
temporal distribution was confirmed, providing an
impetus for the use of FMISO PET imaging in thoracic
oncology. Another limitation of this as well as earlier
PET reproducibility studies in NSCLC is the absence of
respiratory gating [21–23]. While motion correction is
not yet widely used clinically [22], it may alter the accur-
acy of quantitative uptake measures due to image blur-
ring [25]. However, similar reproducibility of FMISO
was observed for non-small cell lung cancer patients as
for patients with head and neck cancer [19], despite the
fact that the latter were immobilized during image
acquisition, the tumours were not affected by respiratory
motion, and for which the co-registration is expected to
be more accurate. Lastly, the clinical significance of the
observed variability in FMISO intratumour distribution in
the context of patient stratification for hypoxia-targetingtherapies, monitoring treatment response, efficacy of bio-
logically conformal radiotherapy, or radiomics warrants
further examination in larger datasets.
Conclusions
The results of this pilot study confirm that (i) FMISO
intratumour distribution is highly reproducible in NSCLC,
facilitating its use in dose escalation of hypoxic tumour
sub-volumes, patient stratification strategies, and monitor-
ing treatment response; (ii) high reproducibility can be
achieved with relatively shorter imaging times post-
injection than those previously suggested, potentially re-
ducing long patient waiting periods; and (iii) the spatio-
temporal uptake patterns of FMISO as measured by PET
are not expected to be affected by transient hypoxia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MG, AR, HS, JLH, and SAN conceived the project. All authors participated in
the data collection and processing. MG and SAN analysed the data. MG
wrote the manuscript. All authors reviewed the manuscript. All authors read
and approved the final manuscript.
Author details
1Department of Medical Physics, Memorial Sloan Kettering Cancer Center,
1275 York Avenue, New York, NY 10065, USA. 2Department of Radiation
Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY, USA. 4National Center for Cancer Care and Research, Doha, Qatar.
Received: 3 June 2016 Accepted: 16 June 2016
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. Epub 2015/02/06. eng.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical
outcome. Cancer Metastasis Rev. 2007;26(2):225–39. Epub 2007/04/19. eng.
3. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging
hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):
674–87. Epub 2012/11/15. eng.
4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation
predicts radiation response in advanced squamous cell carcinoma of the
head and neck. Radiother Oncol. 1996;41(1):31–9. Epub 1996/10/01. eng.
5. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC.
Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat
Oncol Biol Phys. 2009;73(4):1177–86. Pubmed Central PMCID: PMC2680715.
Epub 2009/03/03. eng.
6. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al.
Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J
Radiat Oncol Biol Phys. 1992;22(1):199–212. Epub 1992/01/01. eng.
7. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al.
Quantifying regional hypoxia in human tumors with positron emission
tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.
Int J Radiat Oncol Biol Phys. 1996;36(2):417–28. Epub 1996/09/01. eng.
8. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J,
et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron
emission tomography in head and neck cancer. Clin Cancer Res. 2006;
12(18):5435–41. Epub 2006/09/27. eng.
9. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al.
Evaluation of oxygenation status during fractionated radiotherapy in
human nonsmall cell lung cancers using [F-18]fluoromisonidazole
positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33(2):
391–8. Epub 1995/09/30. eng.
Grkovski et al. EJNMMI Research  (2016) 6:79 Page 9 of 910. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F]
fluoromisonidazole and [18F] fluorodeoxyglucose positron emission
tomography in response evaluation after chemo-/radiotherapy of non-
small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
Pubmed Central PMCID: PMC1456976. Epub 2006/03/07. eng.
11. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al.
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small
cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med.
2005;46(2):253–60. Epub 2005/02/08. eng.
12. Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, et al.
Characterization of hypoxia in malignant pleural mesothelioma with FMISO
PET-CT. Lung Cancer (Amsterdam, Netherlands). 2015;90(1):55–60. Epub
2015/08/12. eng.
13. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-
labeled fluoromisonidazole positron emission and computed tomography-
guided intensity-modulated radiotherapy for head and neck cancer: a feasibility
study. Int J Radiat Oncol Biol Phys. 2008;70(1):2–13. Pubmed Central PMCID:
PMC2888477, Epub 2007/09/18. eng.
14. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact
of FDG-PET on radiation therapy volume delineation in non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys. 2004;59(1):78–86. Epub 2004/04/20. eng.
15. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-
CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC):
the technical basis, ICRU-target volumes, problems, perspectives. Radiother
Oncol. 2006;81(2):209–25. Epub 2006/10/27. eng.
16. Vanderstraeten B, Duthoy W, De Gersem W, De Neve W, Thierens H.
[18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET)
voxel intensity-based intensity-modulated radiation therapy (IMRT) for head
and neck cancer. Radiother Oncol. 2006;79(3):249–58. Epub 2006/03/28. eng.
17. Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided and
intensity-modulated radiotherapy. J Nucl Med. 2009;50(10):1655–65.
Pubmed Central PMCID: PMC2899678, Epub 2009/09/18. eng.
18. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al.
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in
head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235–42.
Pubmed Central PMCID: PMC2837596, Epub 2007/12/19. eng.
19. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High
reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for
head and neck cancer. J Nucl Med. 2013;54(2):201–7. Epub 2013/01/17. eng.
20. Bland JM, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. Lancet. 1986;1(8476):307–10. Epub
1986/02/08. eng.
21. Nakamoto Y, Zasadny KR, Minn H, Wahl RL. Reproducibility of common semi-
quantitative parameters for evaluating lung cancer glucose metabolism with
positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol
Imaging Biol. 2002;4(2):171–8. Epub 2003/10/11. eng.
22. Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, et al.
Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer:
prospective assessment in 2 multicenter trials. J Nucl Med. 2015;56(8):1137–
43. Epub 2015/04/25. eng.
23. Zegers CM, van Elmpt W, Szardenings K, Kolb H, Waxman A, Subramaniam RM,
et al. Repeatability of hypoxia PET imaging using [(18)F]HX4 in lung and head
and neck cancer patients: a prospective multicenter trial. Eur J Nucl Med Mol
Imaging. 2015;42(12):1840–9. Pubmed Central PMCID: PMC4589564, Epub
2015/07/03. eng.
24. Boellaard R. Standards for PET image acquisition and quantitative data
analysis. J Nucl Med. 2009;50 Suppl 1:11S–20S. Epub 2009/04/22. eng.
25. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, et al.
Effect of respiratory gating on quantifying PET images of lung cancer.
J Nucl Med. 2002;43(7):876–81. Epub 2002/07/05. eng.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
